Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma
- PMID: 18455321
- DOI: 10.1016/j.ijrobp.2008.01.058
Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma
Abstract
Purpose: To report our initial experience using intensity-modulated radiotherapy (IMRT) with a cone-down boost for pediatric head-and-neck rhabdomyosarcoma (RMS).
Methods and materials: A review of institutional treatment records identified children treated with IMRT for head-and-neck RMS between January 2000 and February 2007. All patients had undergone chemotherapy according to cooperative group RMS protocols. The initial planning target volume (PTV) covered the prechemotherapy tumor extent with variable margins, generally 1-2 cm. The boost PTV covered the postchemotherapy tumor volume, usually with a margin of 0.5-1 cm.
Results: A total of 20 patients were treated with IMRT for head-and-neck RMS. Of these 20 patients, 4 had Group II, 15 Group III, and 1 Group IV disease. The site was parameningeal in 12, nonparameningeal in 6, and orbit primary in 2. Of the 20 patients, 14 were treated with a cone-down boost after a median dose of 36 Gy (range, 30-45.6). The mean initial PTV was 213.5 cm(3), and the mean boost PTV was 76.9 cm(3). Patients received a median total dose of 50.4 Gy. The median follow-up time was 29 months. The 3-year Kaplan-Meier local control rate was 100%, although 1 patient developed an in-field recurrence 50 months after IMRT. The 3-year event-free survival rate, overall survival rate, and risk of central nervous system failure was 74%, 76%, and 7%, respectively.
Conclusions: Our preliminary follow-up of pediatric head-and-neck RMS patients treated with IMRT revealed excellent local control. The initial targeting of the prechemotherapy tumor volume with 1-2-cm margin to 30.6 or 36 Gy followed by a cone-down boost to the postchemotherapy tumor volume with a 0.5-1-cm margin allowed for significant sparing of normal tissues and provided good local control.
Similar articles
-
Parameningeal rhabdomyosarcoma: outcomes and opportunities.Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e61-6. doi: 10.1016/j.ijrobp.2012.08.019. Epub 2012 Sep 25. Int J Radiat Oncol Biol Phys. 2013. PMID: 23021437
-
Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1294-9. doi: 10.1016/s0360-3016(02)04290-6. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654440 Review.
-
Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1151-1157. doi: 10.1016/j.ijrobp.2018.11.049. Epub 2018 Nov 30. Int J Radiat Oncol Biol Phys. 2019. PMID: 30508617 Free PMC article.
-
Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: implications for patterns of disease recurrence and overall survival.Cancer. 2013 Apr 15;119(8):1578-85. doi: 10.1002/cncr.27934. Epub 2012 Dec 27. Cancer. 2013. PMID: 23280478
-
[Target volume delineation for head and neck cancer intensity-modulated radiotherapy].Cancer Radiother. 2011 Oct;15(6-7):466-72. doi: 10.1016/j.canrad.2011.07.239. Epub 2011 Aug 30. Cancer Radiother. 2011. PMID: 21880533 Review. French.
Cited by
-
Practice patterns and recommendations for pediatric image-guided radiotherapy: A Children's Oncology Group report.Pediatr Blood Cancer. 2020 Oct;67(10):e28629. doi: 10.1002/pbc.28629. Epub 2020 Aug 9. Pediatr Blood Cancer. 2020. PMID: 32776500 Free PMC article.
-
Custom-designed mouthpiece for HDR brachytherapy of embryonal rhabdomyosarcoma of the soft palate.J Contemp Brachytherapy. 2014 Oct;6(3):300-3. doi: 10.5114/jcb.2014.44977. Epub 2014 Aug 29. J Contemp Brachytherapy. 2014. PMID: 25337134 Free PMC article.
-
Proton Radiotherapy to Reduce Late Complications in Childhood Head and Neck Cancers.Int J Part Ther. 2021 Jun 25;8(1):155-167. doi: 10.14338/IJPT-20-00069.1. eCollection 2021 Summer. Int J Part Ther. 2021. PMID: 34285943 Free PMC article.
-
Current and Future Treatment Strategies for Rhabdomyosarcoma.Front Oncol. 2019 Dec 20;9:1458. doi: 10.3389/fonc.2019.01458. eCollection 2019. Front Oncol. 2019. PMID: 31921698 Free PMC article. Review.
-
What is new in rhabdomyosarcoma management in children?Paediatr Drugs. 2012 Dec 1;14(6):389-400. doi: 10.2165/11599440-000000000-00000. Paediatr Drugs. 2012. PMID: 23050743 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical